Hospice Care Market - Strategic Insights and Forecasts (2025-2030)

Hospice Care Market, at a 6.55% CAGR, is anticipated to reach USD 115.716 billion in 2030 from USD 84.279 billion in 2025.

The hospice care market is currently undergoing a period of intense vertical integration as major insurance conglomerates are acquiring large-scale providers to control end-of-life costs. Payers are responding to rising medical expenditures by shifting patients into home-based settings. This transition is becoming critical as the Centers for Medicare & Medicaid Services (CMS) is implementing the Hospice Outcomes & Patient Evaluation (HOPE) instrument in FY 2026 to mandate more granular, patient-level data collection. Regulatory oversight is increasing via the Department of Justice (DOJ), which recently required the divestiture of over 160 locations to preserve competition during the Optum-Amedisys merger. Consequently, the industry is reaching a structural outcome where "Routine Home Care" dominates service delivery, accounting for the highest portion of Medicare hospice days.

Market Dynamics

Drivers

• Global Demographic Aging: The irreversible trend of an aging population is currently fueling the demand for specialized care as the incidence of chronic conditions like cancer and kidney disease rises.

• Value-Based Care Integration: Healthcare systems are currently enlisting hospice services earlier in the disease trajectory to reduce expensive emergency department visits and readmissions.

• Societal Acceptance: Public education initiatives are successfully reducing the historical stigma around end-of-life care, leading to higher utilization rates across all ethnic groups.

• Standardized Medicare Reimbursement: Reliable federal funding via the Medicare Hospice Benefit is currently providing a stable revenue stream for providers expanding into underserved rural markets.

Restraints and Opportunities

• Stricter Antitrust Scrutiny: Increased regulatory oversight from the DOJ is currently complicating large-scale acquisitions, as seen in the mandatory divestitures required for the Amedisys-Optum deal.

• Labor Shortages: The industry is continuing to struggle with a deficit of specialized nurses and case managers, forcing providers to increase wages and productivity incentives.

• Interoperability and Tech (Opportunity): The promotion of Fast Healthcare Interoperability Resources (FHIR) standards is creating a significant opening for digital quality measurement and seamless data exchange.

• Health Equity Initiatives (Opportunity): Progress in enabling access for terminally ill Hispanic and Native American beneficiaries is currently providing a pathway to expand market penetration in diverse communities.

Supply Chain Analysis

The supply chain for hospice care is currently shifting toward a decentralized "Care-at-Home" model where the primary logistics focus is on mobile nursing staff and durable medical equipment (DME) delivery. Providers are increasing their investment in telehealth and remote monitoring tools to manage patient symptoms without requiring physical inpatient beds. This evolution is becoming critical as the termination of the Medicare Advantage hospice demonstration program in 2024 is currently pushing beneficiaries back toward traditional Medicare for their hospice benefits.

Government Regulations

Key Developments

• 2025 Facts and Figures Release (March 2026): The National Alliance for Care at Home published new data showing that hospice utilization has reached its highest historical level, with 1.91 million Medicare decedents enrolled.

• Optum-Amedisys Merger Closure (August 2025): UnitedHealth Group finalized the $3.3 billion acquisition of Amedisys after reaching a settlement with the DOJ that involved divesting $528 million in revenue to BrightSpring and Pennant.

Market Segmentation

By Type

Routine Home Care remains the dominant segment, as 90% of hospice stays are currently managed in the patient's place of residence. CMS is currently finalizing separate payment rates for Routine Home Care based on the length of stay, with higher rates for days 1–60 ($230.83) compared to days 61+ ($181.94). This structural pricing encourages early admission while the General Inpatient and Respite Care segments are witnessing steady demand for short-term symptom management and caregiver relief.

By Age Group

The Elderly segment (age 65+) is currently accounting for the vast majority of demand, as circulatory conditions and neurovascular diseases represent over 50% of hospice stays. Adult hospice care is continuing to grow as specialized palliative protocols are integrated into oncology treatments for younger patients. Pediatric hospice (Children) remains a highly specialized niche where interdisciplinary teams are currently enlisting unique emotional and developmental support for families.

By End-User

Homes are the primary site of service, currently benefiting from the growing "Payvider" preference for low-cost, decentralized care models. Hospitals and Nursing Centers are currently functioning as critical referral sources, though they are increasingly shifting stable patients to home-based hospice to free up high-acuity beds. This movement is resulting in a market where "Home" care is reaching an outcome of nearly universal patient preference for end-of-life settings.

Regional Analysis

North America represents the most mature market, characterized by extensive clinical experience and high public awareness of the Medicare Hospice Benefit. Europe is witnessing increased demand in Germany and France as healthcare systems are currently adopting value-based principles to manage an aging population. In the Asia-Pacific region, Japan and China are currently enlisting hospice care as a standard component of medical treatment to address the high prevalence of chronic diseases in their rapidly aging demographics.

List of Companies

• Amedisys Inc.

• Chemed Corporation (VITAS Healthcare)

• Humana Inc. (CenterWell)

• LHC Group, Inc.

• AccentCare Inc.

• Compassus

• Enhabit Home Health & Hospice

• Gentiva

• Crossroads Hospice & Palliative Care

• Caris Healthcare, L.P.

Company Profiles

• Humana Inc. (CenterWell): Strategically distinct for its "holistic and personalized" senior care model, the company is successfully integrating primary care and pharmacy services with hospice to improve patient outcomes.

• Chemed Corporation (VITAS): Notable for its pure-play leadership in high-acuity hospice care, the company is currently maintaining a robust presence in General Inpatient Care across major urban markets.

• UnitedHealth Group (Optum/LHC/Amedisys): Distinguished by its massive scale, the company is successfully utilizing its "Payvider" status to serve customers at the lowest-cost sites while managing approximately 30% of the market in several US states.

Analyst View

The hospice care market is entering a "Vertical Integration" phase. Success for participants now depends on navigating stricter DOJ antitrust scrutiny and successfully implementing the 2026 HOPE quality reporting mandates to secure value-based contracts through 2031.

Hospice Care Market Scope: